For research use only. Not for therapeutic Use.
SB239063（Cat No.:I002473）is a potent, selective inhibitor of p38 MAPK (mitogen-activated protein kinase), specifically targeting the α and β isoforms. p38 MAPK is a key regulator of inflammatory responses, stress signaling, and apoptosis. By inhibiting p38, SB239063 reduces the production of pro-inflammatory cytokines such as TNF-α and IL-1β, making it valuable for research into inflammation and autoimmune diseases. It has applications in studying inflammatory disorders, cancer, and neurodegenerative diseases where p38 MAPK plays a role. SB239063 is a useful tool for understanding p38 MAPK signaling and its potential as a therapeutic target.
| Catalog Number | I002473 |
| CAS Number | 193551-21-2 |
| Synonyms | 4-(4-(4-fluorophenyl)-5-(2-methoxypyrimidin-4-yl)-1H-imidazol-1-yl)cyclohexanol |
| Molecular Formula | C₂₀H₂₁FN₄O₂ |
| Purity | ≥95% |
| Target | p38 |
| Solubility | 10 mM in DMSO |
| Storage | Store at -20°C |
| IC50 | 44 nM ( p38α) |
| IUPAC Name | 4-[4-(4-fluorophenyl)-5-(2-methoxypyrimidin-4-yl)imidazol-1-yl]cyclohexan-1-ol |
| InChI | InChI=1S/C20H21FN4O2/c1-27-20-22-11-10-17(24-20)19-18(13-2-4-14(21)5-3-13)23-12-25(19)15-6-8-16(26)9-7-15/h2-5,10-12,15-16,26H,6-9H2,1H3 |
| InChIKey | ZQUSFAUAYSEREK-UHFFFAOYSA-N |
| SMILES | COC1=NC=CC(=N1)C2=C(N=CN2C3CCC(CC3)O)C4=CC=C(C=C4)F |
| Reference | </br>1:Effect of the p38 MAPK inhibitor SB-239063 on Lipopolysaccharide-induced psychomotor retardation and peripheral biomarker alterations in rats. Bison S, Razzoli M, Arban R, Michielin F, Bertani S, Carboni L.Eur J Pharmacol. 2011 Jul 1;661(1-3):49-56. doi: 10.1016/j.ejphar.2011.04.020. Epub 2011 Apr 27. PMID: 21545800 </br>2:The selective p38 inhibitor SB-239063 protects primary neurons from mild to moderate excitotoxic injury. Legos JJ, McLaughlin B, Skaper SD, Strijbos PJ, Parsons AA, Aizenman E, Herin GA, Barone FC, Erhardt JA.Eur J Pharmacol. 2002 Jun 28;447(1):37-42. PMID: 12106800 </br>3:SB-239063, a potent and selective inhibitor of p38 map kinase: preclinical pharmacokinetics and species-specific reversible isomerization. Ward KW, Proksch JW, Azzarano LM, Salyers KL, McSurdy-Freed JE, Molnar TM, Levy MA, Smith BR.Pharm Res. 2001 Sep;18(9):1336-44. PMID: 11683250 </br>4:SB 239063, a novel p38 inhibitor, attenuates early neuronal injury following ischemia. Legos JJ, Erhardt JA, White RF, Lenhard SC, Chandra S, Parsons AA, Tuma RF, Barone FC.Brain Res. 2001 Feb 16;892(1):70-7. PMID: 11172750 </br>5:SB 239063, a second-generation p38 mitogen-activated protein kinase inhibitor, reduces brain injury and neurological deficits in cerebral focal ischemia. Barone FC, Irving EA, Ray AM, Lee JC, Kassis S, Kumar S, Badger AM, White RF, McVey MJ, Legos JJ, Erhardt JA, Nelson AH, Ohlstein EH, Hunter AJ, Ward K, Smith BR, Adams JL, Parsons AA.J Pharmacol Exp Ther. 2001 Feb;296(2):312-21. PMID: 11160612 Free Article</br>6:SB 239063, a p38 MAPK inhibitor, reduces neutrophilia, inflammatory cytokines, MMP-9, and fibrosis in lung. Underwood DC, Osborn RR, Bochnowicz S, Webb EF, Rieman DJ, Lee JC, Romanic AM, Adams JL, Hay DW, Griswold DE.Am J Physiol Lung Cell Mol Physiol. 2000 Nov;279(5):L895-902. PMID: 11053025 Free Article</br>7:SB 239063, a potent p38 MAP kinase inhibitor, reduces inflammatory cytokine production, airways eosinophil infiltration, and persistence. Underwood DC, Osborn RR, Kotzer CJ, Adams JL, Lee JC, Webb EF, Carpenter DC, Bochnowicz S, Thomas HC, Hay DW, Griswold DE.J Pharmacol Exp Ther. 2000 Apr;293(1):281-8. PMID: 10734180 Free Article |
